Al-Azhar University hospitals
Asyut, Egypt
NCT Number: NCT06590831
Iron deficiency (ID) and iron deficiency anemia (IDA) are the most common iron disorders throughout the world.
ID and IDA, particularly caused by increased iron requirements during pregnancy; represent a high risk for preterm delivery, fetal growth retardation, low birth weight, and inferior neonatal health. These pregnancy complications are thought to occur because of an increased iron requirement, related to enhanced blood volume and development of the fetoplacental unit.
Looking for future studies?
Notify Me20 year–35 year
Female
Interventional
Not applicable
Asyut, Egypt
The World Health Organization (WHO) defines anemia in pregnancy as a hemoglobin (Hb) concentration of < 11 g/dl. Centers for disease control &prevention determine a cut of -off point 10.5 g/dl during 2nd trimester for diagnosis of IDA.
Iron deficiency anemia (IDA) is the most common type of anemia in pregnancy. The iron content of the body is normally kept constant by regulating the amount absorbed to balance the amount lost.
The WHO estimates that 46% of pregnant women in African region, 38% in Eastern Mediterranean region, 25% in European region and 24% in the region of the Americas are anemic mainly because of iron deficiency. Anemia is a common medical disorder affecting a lot of women in pregnancy in the developing countries.
Management of anemia remain an important issue in prenatal medicine. Correct diagnosis and treatment lead to effective management of fetal and maternal risk and improved prenatal outcome. Diet alone can't supply the 30-40 mg iron that is required for absorption of 4-6mg iron per day needed during the later stage of pregnancy so iron supplementation is strongly recommended for all females in developing countries.
Traditional therapeutic options of iron deficiency anemia during pregnancy were administration of oral iron shows lack of compliance and side effects and often limited intestinal absorption and bioavailability. The most used treatment for ID and IDA currently consists of oral administration of iron as ferrous sulphate. However, ferrous sulphate administration often fails to exert any significant effects on these pregnancy-associated pathologies, and frequently causes several adverse effects.
This is likely due to the poor bioavailability of inorganic iron requiring the administration of large quantity of ferrous sulphate. Lactoferrin is a multifunctional protein of the transferrin family. Lactoferrin is a globular glycoprotein with a molecular mass of about 80 kDa that is widely represented in various secretory fluids, such as milk, saliva, tears, and nasal secretions. Lactoferrin is also present in secondary granules of Polymorpho nuclear leucocyte and is secreted by some acinar cells. Lactoferrin can be purified from milk or produced recombinantly .
Lactoferrin (previously lactotransferrin)is a glycoprotein that belongs to transferrin family ,which includes protiens that may bind &transferrin.Lactoferrin levels in cow milk &human milk colostrum are roughly seven times higher than lactoferrin levels in milk prouduced later
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
to compare between efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy
Other names: Iron
Time frame: 6 months
Efficacy of lactoferrin alone and lactoferrin with iron for treatment of iron deficiency anemia during 3rd trimester of pregnancy by measuring the hemoglobin level before and after treatment
Egymedicalpedia
Industry
Lactoferrin Alone ,Iron Alone Vs Lactoferrin Plus Iron for Treatment of Iron Deficiency Anemia During the 3rd Trimester of Pregnancy (Randomized Controlled Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07267975
Anemia, Anemia, Hypochromic
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT06104800
Anemia, Anemia, Hypochromic
México, Mexico
View Trial DetailsNCT03817957
Anemia, Anemia, Hypochromic
Frankfurt, Hessia, Germany
View Trial DetailsNCT06238895
Anemia, Anemia, Hypochromic
Lucerne, Switzerland
View Trial Details